GlassScriptPhysician profile
Raymond T Root
NPI 1366290843
$972.38
in general payments reported to CMS, 2019-2025
9 companies · $535 in 2025
The $535 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $438 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.63 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $199.63 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $167.40 | 2024-2025 | Pulmicort |
| Lilly USA, LLC | $75.95 | 2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $36.00 | 2025 | Quviviq |
| Exact Sciences Corporation | $31.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.37 | 2024-2025 | Caplyta |
| Abbott Laboratories | $22.21 | 2025 | Freestyle Libre |
| Kowa Pharmaceuticals America, INC. | $17.66 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Root listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.